Velsipity in Practice:
Ulcerative Colitis (UC) Launch Series

Select your state

VELSIPITY is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had inadequate response, loss of response or intolerance to conventional, biologic or Janus kinase (JAK) inhibitor therapies.¹

PBS information: VELSIPITY is not listed on the PBS.

This medicinal product is subject to additional monitoring in Australia. This will allow quick identiﬁcation of new safety information.
Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

BEFORE PRESCRIBING, PLEASE REVIEW PRODUCT INFORMATION AVAILABLE
BY CLICKING THE LINK, SCANNING THE QR CODE OR CALLING 1800 675 229.

Medical Information Australia : 1800 675 229,
www.pfizermedicalinformation.com.au

Privacy Policy and Terms of Use available at: www.pfizer.com.au

Velsipity in Practice: Ulcerative Colitis (UC) Launch Series

Select your state

Velsipity in Practice:
Ulcerative Colitis (UC) Launch Series